[Other] ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer and residua...

Closed

Feraldac Post time 2024-5-3 03:36:40 | Show all posts |Read mode

Reward20points

journal：Journal of Clinical Oncology

Authors：Sara M. Tolaney; Angela DeMichele; Toshimi Takano; Hope S. Rugo; Charles Perou; Otto Metzger; Heather Anne Parsons; Cesar Augusto Santa-Maria; Gabrielle Betty Rocque; Wenliang Yao; Shawn W. Sun; Simonetta Mocci; Ann H. Partridge; Lisa A. Carey

Published date：2023-6-1

DOI：10.1200/jco.2023.41.16_suppl.tps619

PDF link：https://ascopubs.org/doi/pdfdire ... .41.16_suppl.TPS619

Article link：http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps619

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

Feraldac Lv.2

Junior Member

post
reply
points
180

[Other] ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer and residua...

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer and residua... Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer and residua...